Table 1. Patients' characteristics.
| Characteristic | Value (n = 957) | |
|---|---|---|
| Sex (male:female) | 5 (0.5):952 (99.5) | |
| Age, median (range) | 50 (22–81) | |
| Menopausal status (pre-menopause:post-menopause) | 511 (53.4):446 (46.6) | |
| Surgery (mastectomy:BCS) | 353 (36.9):604 (63.1) | |
| Histology (IDC/ILC/other) | 846 (88.4)/48 (5.0)/63 (6.6) | |
| Pathological stage | ||
| 0 | 4 (0.4)* | |
| IA/IB | 435 (45.5)/7 (0.7) | |
| IIA/IIB | 289 (30.2)/124 (13.0) | |
| IIIA/IIIB/IIIC | 66 (6.9)/1 (0.1)/31 (3.2) | |
| Neoadjuvant chemotherapy | 151 (15.8) | |
| Adjuvant treatment | ||
| Chemotherapy | 508 (53.1) | |
| Radiation therapy | 615 (64.3) | |
| Hormonal therapy | 720 (99.8% of hormone receptor positive patients) | |
| Trastuzumab | 136 (90.1% of HER2-positive patients) | |
| Breast cancer subtypes | ||
| Luminal A | 346 (36.2) | |
| Luminal B (HER2-negative/-positive) | 305 (31.9)/70 (7.3) | |
| HER2-positive | 81 (8.5) | |
| Triple-negative | 155 (16.2) | |
Values are presented as number (%).
BCS = breast-conserving surgery; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; HER2 = human epidermal growth factor receptor 2.
*Pathologic complete response (ypT0/Tis ypN0) after neoadjuvant chemotherapy.